Breast Cancer Updates and T-Cell Stemness
from OncoPharm Hosted by John Bossaer
This week we discuss a new approval for pabociclib in HER2-positive disease based on the PATINA trial as well as the use of sacituzumab govitecan + pembrolizumab in TNBC, recently approved based on the ASCENT04/KEYNOTED19 trial. And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002 Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 19 minutes long.
When was this OncoPharm episode published?
This episode was published on June 25, 2026.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.